Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis.
Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis.
复制标题
DOI：
10.1186/s12959-018-0182-4
复制
发表时间：
2018
影响因子：
3.1
通讯作者：
Monagle P
中科院分区：
文献类型：
--
作者：
Chan A;Lensing AWA;Kubitza D;Brown G;Elorza D;Ybarra M;Halton J;Grunt S;Kenet G;Bonnet D;Santamaria A;Saracco P;Biss T;Climent F;Connor P;Palumbo J;Thelen K;Smith WT;Mason A;Adalbo I;Berkowitz SD;Hurst E;van Kesteren J;Young G;Monagle P
幼儿静脉血栓栓塞（VTE）尚无充分记录。来自 12 个机构的临床医生回顾性评估了 2011 年至 2016 年 2 岁以下儿童 VTE 的表现、治疗管理和结果。在小爱因斯坦中招募这些孩子的可行性。 III 期是一项评估利伐沙班与标准抗凝治疗 VTE 的随机试验。我们确定了 346 名患有 VTE 的儿童，其中 227 名 (65.6%) 患有中心静脉导管相关血栓 (CVC-VTE)，119 名 (34.4%) 患有非 CVC-VTE，156 名 (45.1%) 年龄小于 1 个月。在接受抗凝治疗的 309 名儿童中，86 名 (27.8%) 的治疗持续时间较短（即 CVC-VTE 治疗时间< 6 周，非 CVC-VTE 治疗时间< 3 个月），17 名儿童 (5.5%) 在抗凝治疗期间或停药后不久出现 VTE 复发 (n = 8, 2.6%) (n = 9, 2.9%)。共有 37 名（10.7%）儿童未接受抗凝治疗，4 名（10.5%）儿童出现复发性 VTE。每个站点每年考虑入读 EINSTEIN-Jr 的年龄 <0.5 岁和 0.5-2 岁儿童的平均人数分别约为 1.0 名和 0.9 名。患有 VTE 的幼儿最常见的是 CVC-VTE，大约十分之一和四分之一的儿童分别没有接受或仅接受过短期抗凝治疗。未经抗凝治疗、抗凝治疗期间或停药后不久的 VTE 复发率似乎与成人中观察到的相似。短而灵活的治疗持续时间可能会增加小爱因斯坦的招募。第三阶段。
Venous thromboembolism (VTE) in young children is not well documented. Clinicians from 12 institutions retrospectively evaluated the presentation, therapeutic management, and outcome of VTE in children younger than 2 years seen in 2011–2016. Feasibility of recruiting these children in EINSTEIN-Jr. phase III, a randomized trial evaluating rivaroxaban versus standard anticoagulation for VTE, was assessed. We identified 346 children with VTE, of whom 227 (65.6%) had central venous catheter-related thrombosis (CVC-VTE), 119 (34.4%) had non-CVC-VTE, and 156 (45.1%) were younger than 1 month. Of the 309 children who received anticoagulant therapy, 86 (27.8%) had a short duration of therapy (i.e. < 6 weeks for CVC-VTE and < 3 months for non-CVC-VTE) and 17 (5.5%) had recurrent VTE during anticoagulation (n = 8, 2.6%) or shortly after its discontinuation (n = 9, 2.9%). A total of 37 (10.7%) children did not receive anticoagulant therapy and 4 (10.5%) had recurrent VTE. The average number of children aged < 0.5 years and 0.5–2 years who would have been considered for enrolment in EINSTEIN-Jr is approximately 1.0 and 0.9 per year per site, respectively. Young children with VTE most commonly have CVC-VTE and approximately one-tenth and one-fourth received no or only short durations of anticoagulant therapy, respectively. Recurrent VTE rates without anticoagulation, during anticoagulation or shortly after its discontinuation seem comparable to those observed in adults. Short and flexible treatment durations could potentially increase recruitment in EINSTEIN-Jr. phase III.
登录
查看更多内容
影响因子：
2.7
作者：
Taylor, Sarah N.;Basile, Laura A.;Wagner, Carol L.
通讯作者：
Wagner, Carol L.
影响因子：
7.5
作者：
Jaffray, Julie;Mahajerin, Arash;Branchford, Brian
通讯作者：
Branchford, Brian
DOI：
10.1136/fn.75.2.f117
发表时间：
1996-09-01
影响因子：
4.4
作者：
Ewer, AK;Durbin, GM;Booth, IW
通讯作者：
Booth, IW
影响因子：
4.3
作者：
Sandoval, John A.;Sheehan, Michael P.;Dalsing, Michael C.
通讯作者：
Dalsing, Michael C.
影响因子：
4.5
作者：
Mueck, Wolfgang;Stampfuss, Jan;Kubitza, Dagmar;Becka, Michael
通讯作者：
Becka, Michael